Drug Trial Radar · NCT07933445
VIS954 for Treating Inflammatory Skin Problems
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Mar 13, 2029
Study completion Mar 13, 2029
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, multicenter, basket study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of VIS954 in adults with inflammatory skin diseases (ISDs).
Conditions
- Inflammatory Skin Diseases
Interventions
VIS954Drug
VIS954 solution for injection
PlaceboDrug
VIS954-matching placebo solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- HS, PG, and BP Cohorts: Incidence Assessed as Number of Adverse Events (AEs) and AEs Related to InfectionTime frame: Up to Week 36
- HS, PG, and BP Cohorts: Incidence Assessed as Number of Clinically Significant Laboratory Abnormalities' EventsTime frame: Up to Week 36
- HS, PG, and BP Cohorts: Incidence Assessed as Number of Clinically Significant Vital Signs' EventsTime frame: Up to Week 36
- HS, PG, and BP Cohorts: Incidence Assessed as Number of Clinically Significant Physical Examination EventsTime frame: Up to Week 36
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.